A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Enrolling by invitationOBSERVATIONAL

Enrollment

555

Participants

Timeline

Start Date

August 8, 2025

Primary Completion Date

October 21, 2027

Study Completion Date

October 21, 2027

Conditions

Obesity

Interventions

DRUG

Semaglutide

Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.

Trial Locations (1)

Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR, Berlin